Literature DB >> 9242520

Activation of p38 MAP kinase pathway by erythropoietin and interleukin-3.

Y Nagata1, T Moriguchi, E Nishida, K Todokoro.   

Abstract

Activation of p38 MAP kinase (p38) as well as JNK/SAPK has been described as being induced by a variety of environmental stresses such as osmotic shock, ultraviolet radiation, and heat shock, or the proinflammatory cytokines tumor necrosis factor-alpha and interleukin-1 (IL-1). We found that the hematopoietic cytokines erythropoietin (Epo) and IL-3, which regulate growth and differentiation of erythroids and hematopoietic progenitors, respectively, also activate a p38 cascade. Immunoblot analyses and in vitro kinase assay clearly showed that Epo and IL-3 rapidly and transiently phosphorylated and activated p38 in Epo- or IL-3-dependent mouse hematopoietic progenitor cells. p38 can generally be activated by the upstream kinase MKK3 or MKK6. However, in vitro kinase assays in the immunoprecipitates with anti-MKK6 antibody and anti-phosphorylated MKK3/MKK6 antibody showed that activation of neither MKK3 nor MKK6 was detected after Epo or IL-3 stimulation, while osmotic shock clearly induced activation of both MKK3/MKK6 and p38. Together with previous observations, these results suggest that both p38 and JNK cascades play an important role not only in stress and proinflammatory cytokine responses but also in hematopoietic cytokine actions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9242520

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

Review 1.  Cytokine signaling to the cell cycle.

Authors:  Frederick W Quelle
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

2.  p38α controls erythroblast enucleation and Rb signaling in stress erythropoiesis.

Authors:  Simon M Schultze; Andreas Mairhofer; Dan Li; Jin Cen; Hartmut Beug; Erwin F Wagner; Lijian Hui
Journal:  Cell Res       Date:  2011-09-27       Impact factor: 25.617

3.  Activation of the Jun N-terminal kinase pathway by friend spleen focus-forming virus and its role in the growth and survival of friend virus-induced erythroleukemia cells.

Authors:  Kazuo Nishigaki; Charlotte Hanson; Delores Thompson; Takashi Yugawa; Sandra Ruscetti
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

4.  Retinoic acid selectively activates the ERK2 but not JNK/SAPK or p38 MAP kinases when inducing myeloid differentiation.

Authors:  A Yen; M S Roberson; S Varvayanis
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999-10       Impact factor: 2.416

5.  Lyn is activated during late G1 of stem-cell-factor-induced cell cycle progression in haemopoietic cells.

Authors:  S Mou; D Linnekin
Journal:  Biochem J       Date:  1999-08-15       Impact factor: 3.857

6.  Inhibition of p38 mitogen-activated protein kinase promotes ex vivo hematopoietic stem cell expansion.

Authors:  Yong Wang; Joshua Kellner; Lingbo Liu; Daohong Zhou
Journal:  Stem Cells Dev       Date:  2011-02-24       Impact factor: 3.272

Review 7.  The erythropoietin receptor: molecular structure and hematopoietic signaling pathways.

Authors:  Stephanie S Watowich
Journal:  J Investig Med       Date:  2011-10       Impact factor: 2.895

8.  Inhibition of p38 MAPK activity promotes ex vivo expansion of human cord blood hematopoietic stem cells.

Authors:  Jing Zou; Ping Zou; Jie Wang; Lei Li; Yong Wang; Daohong Zhou; Lingbo Liu
Journal:  Ann Hematol       Date:  2012-01-19       Impact factor: 3.673

9.  PRAK, a novel protein kinase regulated by the p38 MAP kinase.

Authors:  L New; Y Jiang; M Zhao; K Liu; W Zhu; L J Flood; Y Kato; G C Parry; J Han
Journal:  EMBO J       Date:  1998-06-15       Impact factor: 11.598

10.  The signaling pathways of erythropoietin and interferon-gamma differ in preventing the apoptosis of mature erythroid progenitor cells.

Authors:  Kittiphong Paiboonsukwong; Ilseung Choi; Takamitsu Matsushima; Yasunobu Abe; Junji Nishimura; Pranee Winichagoon; Suthat Fucharoen; Hajime Nawata; Koichiro Muta
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.